000			02646na a2200265 4500
999			_c10923 _d10923
003			PC10923
005			20181212125837.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aAragüés Figuero, María _9146 _ePsiquiatría
100			_aPalomo Álvarez, Tomás _9653 _d(1989-2010) _ePsiquiatría
100			_aSanz Fuentenebro, Francisco Javier _91875 _ePsiquiatría
100			_aTaboada, Diana _92460 _ePsiquiatría
245	0	0	_aRandomized trial of clozapine vs. risperidone in treatment-naive first-episode schizophrenia: Results after one year. _h[artículo]
260			_bSchizophrenia Research, _c2013
300			_a149(1-3):156-61.
500			_aFormato Vancouver: Sanz-Fuentenebro J, Taboada D, Palomo T, Aragües M, Ovejero S, Del Alamo C et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophr Res. 2013 Sep;149(1-3):156-61.
501			_aPMID: 23870807
504			_aContiene 32 referencias
520			_aIn first-episode patients with psychosis, clozapine may be potentially valuable as an initial treatment seeking to limit early on clinical and cognitive deterioration. Nevertheless, until recently its restricted use has limited the study of this possibility. Our research group is developing a non-commercial, multicentric and open label study on the differential efficacy between clozapine and risperidone in first-episode schizophrenia. In this paper, we present the results related to clinical variables after a one-year follow-up. So far, we have recruited 30 patients diagnosed with schizophrenia or schizophreniform disorder with illness duration of less than two years. The patients had not received any previous treatment and they were randomized to treatment with clozapine or risperidone. Our results indicate that on average, patients on clozapine adhered to their original treatment for a longer time period than patients on risperidone. By last observation carried forward (LOCF) analysis, patients on clozapine and risperidone displayed similar clinical improvements, although marginally greater improvements in positive and total symptoms scores were found in the clozapine group. At the 12-month point we observed a marginal improvement in negative symptom scores in patients on clozapine. Subjective secondary effects, as measured with the Udvalg for KliniskeUndersogelser (UKU) scale, correlated negatively with negative symptoms at follow-up. Our data, although preliminary, suggest that clozapine may have a slightly superior efficacy in the initial year of treatment of first-episode treatment-naive patients with schizophrenia, and this can be explained for the most part by greater adherence to this treatment.
710			_9150 _aServicio de Psiquiatría
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc10923.pdf _ySolicitar documento
942			_n0 _2ddc _cART